CI
IDXG

Cowen Inc’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Cowen Inc’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-346
Closed -$163K – 303
2013
Q2 		$163K Buy
+346
New +$157K 0.02% 209

Other funds holding IDXG

HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 37.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KSC
Kendall Square Capital San Francisco, California $4.92M AUM 2.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
LCM
Leonard Capital Management Vero Beach, Florida $5.25M AUM

Cowen Inc's IDXG Position: Q3 2013 in Review

Cowen Inc sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q3 2013, closing a stake of 346 shares — an estimated $163K sold.

Cowen Inc first reported a position in IDXG in Q2 2013 and held it in 1 quarter. The position peaked at $163K in Q2 2013. 29 funds tracked by Wall St. Rank hold IDXG as of Q3 2013.

  • Cowen Inc reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q3 2013 after selling out during the quarter.
  • Cowen Inc sold 346 Interpace Biosciences, Inc. Common Stock shares in Q3 2013, an estimated $163K.
  • Cowen Inc first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 1 quarter.
  • Cowen Inc's Interpace Biosciences, Inc. Common Stock position peaked at $163K in Q2 2013.
  • 29 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q3 2013.

Based on Cowen Inc's 13F filing for Q3 2013, filed 15 Nov 2013.